Aileron Therap (NASDAQ:ALRN)‘s stock had its “buy” rating reaffirmed by stock analysts at Canaccord Genuity in a research report issued on Friday. They currently have a $19.00 price objective on the stock. Canaccord Genuity’s target price indicates a potential upside of 55.10% from the stock’s previous close.

Other analysts have also issued reports about the company. Bank of America Corporation assumed coverage on Aileron Therap in a research note on Monday, July 24th. They issued a “buy” rating and a $19.00 price target on the stock. Jefferies Group LLC assumed coverage on Aileron Therap in a research note on Monday, July 24th. They issued a “buy” rating and a $20.00 price target on the stock. Finally, William Blair assumed coverage on Aileron Therap in a research note on Monday, July 24th. They issued an “outperform” rating on the stock.

Aileron Therap (ALRN) traded down 2.62% on Friday, hitting $12.25. The stock had a trading volume of 7,877 shares. The company’s market cap is $180.20 million. Aileron Therap has a 12 month low of $10.73 and a 12 month high of $14.32. The company has a 50-day moving average of $12.80 and a 200 day moving average of $12.80.

TRADEMARK VIOLATION WARNING: This piece was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.watchlistnews.com/aileron-therap-alrn-receives-buy-rating-from-canaccord-genuity/1474343.html.

In other news, Director Reinhard J. Ambros purchased 266,667 shares of the stock in a transaction dated Wednesday, July 5th. The shares were purchased at an average cost of $15.00 per share, with a total value of $4,000,005.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Cvf, Llc purchased 180,000 shares of the stock in a transaction dated Wednesday, July 5th. The stock was purchased at an average cost of $15.00 per share, for a total transaction of $2,700,000.00. The disclosure for this purchase can be found here. Insiders bought 696,667 shares of company stock worth $10,450,005 over the last ninety days. Corporate insiders own 68.10% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in ALRN. Vanguard Group Inc. bought a new position in Aileron Therap during the second quarter worth $111,000. Laurion Capital Management LP bought a new position in Aileron Therap during the second quarter worth $335,000. Sphera Funds Management LTD. bought a new position in Aileron Therap during the second quarter worth $1,394,000. Neuberger Berman Group LLC bought a new position in Aileron Therap during the second quarter worth $279,000. Finally, Jennison Associates LLC bought a new position in Aileron Therap during the second quarter worth $2,788,000. 1.02% of the stock is currently owned by institutional investors.

Aileron Therap Company Profile

Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.

Receive News & Ratings for Aileron Therap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therap and related companies with Analyst Ratings Network's FREE daily email newsletter.